<DOC>
	<DOCNO>NCT00202124</DOCNO>
	<brief_summary>The purpose study determine whether tryptophan effective treatment mild moderate Alzheimer 's Disease ( AD ) .</brief_summary>
	<brief_title>Double Blind Study Trp01 Patients With Alzheimer 's Disease</brief_title>
	<detailed_description>The clinical trial double-blind , placebo-controlled study patient randomize 2:1 ratio group A B , respectively : Group A : TRP01 1g b.i.d . 26 week Group B : placebo capsule b.i.d . 26 week After initial screening , clinic visit take place 0 , 13 26 week . The blinding maintain patient complete 26-week trial . Any patient wish continue take medication upon completion trial provide prescription drug may purchase expense .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Tryptophan</mesh_term>
	<criteria>Patients select order fulfill follow definition : Dementia accord DSMIV criterion : development multiple cognitive deficit manifest memory impairment one follow cognitive disturbance : aphasia , apraxia , agnosia , disturbance executive functioning abovementioned deficit cause significant impairment social occupational functioning occur exclusively course delirium Dementia accord communicative disorder stroke criterion ( NINCDSADRDA ) dementia establish clinically document Folstein MiniMental State Examination ( MMSE ) deficits two area cognition progressive worsen memory cognitive function disturbance consciousness absence systematic disorder brain disease account progressive deficit memory cognition Furthermore , patient must fulfill follow criterion : men , postmenopausal surgically sterilize woman severity dementia mild moderate degree reflect score great 14 less 26 MMSE minimum oneyear duration symptomatology ( progressive worsen memory cognitive function ) live home institution provide reliable caregiver able perform require psychometric test evaluation . Visual auditory acuity ( glass hear aid require ) must sufficient complete protocolspecified procedure . Clinical laboratory battery ( see section 7.2.2 ) must yield result within normal limit determine clinically significant study physician patient ’ sex age Patients substitute decisionmakers must sign write informed consent form Patients follow include study : Patients cause dementia evidence medical history , general physical neurological examination , laboratory test , neuroradiological finding : Vascular dementia , evidence Modified Hachinski Ischemia Scale Depressive pseudementia , evidence cognitive disturbance concomitant major depressive episode accord DSMIV and/or history one major depressive episode DSMIV criterion major psychiatric disorder include schizophrenia , alcohol substance abuse Huntington ’ chorea Parkinson ’ disease , evidence neurological examination , onset prior concurrent dementia CreutzfeldtJakob disease Intracranial mass lesion Clinically important head injury History current evidence stroke Onset dementia follow cardiac arrest heart surgery Neurosyphilis Seropositivity HIV Vitamin B12 deficiency Uncorrected hypothyroidism ( i.e . abnormal free T4 , ultrasensitive TSH ) Patients relevant concomitant disease : Patients history current evidence sleep disorder Patients clinically significant cardiovascular , renal , hepatic , pulmonary , gastrointestinal , endocrine , metabolic , opthalmologic , hematologic condition Current evidence history within past year myocardial infarction ( MI ) , congestive heart failure Blood pressure screen &gt; 180 mm Hg systolic 100 mm Hg diastolic Impaired renal , hepatic , gastrointestinal function , could interfere drug absorption , metabolism excretion Seizure disorder Diabetes Earlier diagnosis current evidence cataract Progressive fatal disease ( AD ) Treatment investigational drug last 8 week prior screen Previous administration TRP01</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
</DOC>